

IDENTIFICATION OF EARLY BIOMARKERS OF ARTERIOVENOUS FISTULA (AVF) STENOSIS: THE ROLE OF CIRCULATING PLASMA MICROVESICLES (MV)

Marita Marengo *, Elisabetta Radin §, Davide Medica #, Pier Eugenio Nebiolo §, Alfonso Pacitti ~, Marco Formica *, Vincenzo Cantaluppi #

* Nephrology and Dialysis Unit, ASLCN1, Medical Department, Cuneo, ITALY

§ Nephrology and Dialysis Unit, Medical Department, Aosta, ITALY

Nephrology and Kidney Transplantation Unit, Department of Translational Medicine, University of Eastern Piedmont, Novara, ITALY

~ Nephrology and Dialysis Unit, Medical Department, Cuneo, ITALY

TOPIC: Dialysis – vascular access

INTRODUCTION AND OBJECTIVES

A functional arteriovenous fistula (AVF) is the mainstay to perform adequate hemodialysis and to improve patient's survival. The primary complication that causes AVF failure is stenosis with subsequent thrombosis [1]. Surveying for stenosis can be performed by different ways: in this study, we first analyzed the role of Glucose Pump Test (GPT), an economic, quick and first level assay, to detect stenosis measuring access recirculation [2,3]; secondly, we evaluated correlations between some clinical parameters and novel biomarkers of microvascular injury such as circulating plasma microvesicles (MV) [4] and endothelial-derived von Willebrand factor (vWF) levels [5] in patients with significant (>50% of the access diameter) AVF stenosis.

METHODS

In the first part of the study, we retrospectively analyzed the results of 65 GPT performed in 31 hemodialysis patients with a critical AVF stenosis. Subsequently, 73 hemodialysis patients were enrolled: significant stenoses were identified by Doppler ultrasound (DUS) [6] and then correlated with socio-demographic parameters, clinical history and data from dialysis, AVF (including results of GPT) and laboratory (including MV phenotypic characterization and concentration of vWF).

RESULTS AND CONCLUSIONS

Retrospective analysis of 31 AVF showed a significant correlation between stenosis occurrence and GPT results (75th percentile value of 666 ml/min) or its variation when performed 6 months before angioplasty (66.1% of data with variation $\geq 25\%$). ROC curve revealed a cut off value of 687 ml/min for the diagnosis of AVF stenosis (figure 1).

DUS analysis of 73 patients showed 22 AVF with significant stenosis and 51 AVF with non significant or absent stenosis. We found a good correlation between significant stenoses and low achievement of prescribed blood flow ($p < 0.001$), low Kt/V, bicarbonate hemodialysis ($p = 0.014$) and previous angioplasty ($p < 0.001$).

Concentration of plasma MV was significantly higher in patients with significant stenosis in comparison to non-complicated AVF (figure 2). Moreover, MV derived from stenotic AVF showed an increased expression of markers typical of endothelium (CD31, CD105, CD146) and platelets (CD41, CD42b, P-selectin) (figure 3).

Furthermore, we observed a significant increase in the concentration of vWF, an established marker of endothelial injury, in AVF stenosis group ($p = 0.001$) (figure 4).

In conclusion, GPT may be considered as a valid first level test for monitoring AVF stenosis. However, in our experience the association between DUS and new biomarkers of microvascular injury, such as vWF and particularly endothelial-/platelet-derived MV, represents a new non-invasive diagnostic tool for monitoring AVF stenosis.




Figure 1. GPT-ROC curve revealed a cut off value of 687 ml/min for the diagnosis of AVF stenosis




Figure 2. Size and concentration of plasma microvesicles in patients with and without significant AVF stenosis




Figure 3. Characterization of microvesicles




Figure 4. Concentration of vWF in patients with and without significant AVF stenosis

REFERENCES

1. Radojica Stolic. Most Important Chronic Complications of Arteriovenous Fistulas for Hemodialysis. Med Princ Pract 2013;22:220–228
2. Bosticardo et al. Two-operator glucose infusion test (GIT2) for vascular access recirculation measurement during hemodialysis. J Vasc Access 2010; 11(1):38-40
3. Magnasco A, Alloatti S, Martinoli C, Solari P. Glucose pump test: a new method for blood flow measurements. Nephrol Dial Transplant 2002;17(12):2244-8
4. Jorgensen MM, Baek R, Varming K. Potentials and capabilities of the extracellular vesicle (EV) array. Journal of Extracellular Vesicles 2015;4:26048
5. Ding J, Chen F. Low paraoxonase 1 arylesterase activity and high von Willebrand factor levels are associated with severe coronary atherosclerosis in patients with non-diabetic stable coronary artery disease. Med Sci Monit. 2014 Nov 25;20:2421-9
6. Bay WH, Henry ML, Lazarus JM, et al. Predicting hemodialysis access failure with color flow Doppler ultrasound. Am J Nephrol 1998;18:296-304